These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26785036)

  • 1. Heart failure associated with small molecule tyrosine kinase inhibitors.
    Imran TF; Shah R; Ha AS; Thomas R; Joseph J
    Int J Cardiol; 2016 Mar; 206():110-1. PubMed ID: 26785036
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor induced pancreatitis.
    Sevin A; Chen A; Atkinson B
    J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
    Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
    J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taking cancer-drug toxicity to heart.
    Rose S
    Cancer Discov; 2013 Feb; 3(2):132. PubMed ID: 23400461
    [No Abstract]   [Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract]   [Full Text] [Related]  

  • 7. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 8. [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
    Pérez López G; Carrasco De La Fuente M; Menacho Román M; González Albarrán O; Cano Megías M
    Endocrinol Nutr; 2011 Feb; 58(2):94-6. PubMed ID: 21333617
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
    Srikanthan A; Ethier JL; Ocana A; Seruga B; Krzyzanowska MK; Amir E
    PLoS One; 2015; 10(3):e0122735. PubMed ID: 25815472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of intermediate-stage hepatocellular carcinoma.
    Finn RS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK; Jarkowski A
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
    [No Abstract]   [Full Text] [Related]  

  • 16. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
    Breaker K; Naam M; La Rosa FG; Flaig IP; Flaig TW
    Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ
    J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
    Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.